2024-10-24 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) has a **cumulative return of 35.69%** compared to the **S&P 500 (VOO) cumulative return of 136.39%**. This indicates a significant **underperformance** of JNJ compared to the benchmark, resulting in a **-100.7% difference** in returns. The **relative divergence** score of **4.23** indicates that JNJ's performance is currently **at the lower end of its historical performance range**.

**Company Overview:**

Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer goods company. It is a leading healthcare provider, known for its diversified product portfolio and strong brand reputation.

**2. Recent Price Movement:**

* **Closing Price:** 162.59
* **5-day Moving Average:** 163.86
* **20-day Moving Average:** 161.88
* **60-day Moving Average:** 162.56

The stock is trading slightly below its 5-day and 60-day moving averages, suggesting a **potential short-term bearish sentiment**. However, the stock is trading above its 20-day moving average, indicating potential for **short-term upside momentum**.

**3. Technical Indicators:**

* **RSI:** 57.03
* **PPO:** 0.16
* **Recent Relative Divergence:** -2.49 (Short-term bearish signal)
* **Expected Return:** 0.0% (Long-term expected return relative to S&P 500)

The **RSI** is above 50, indicating a bullish momentum, while the **PPO** is positive, suggesting a potential for further upward movement. However, the **negative recent relative divergence** suggests a **short-term downward trend**. The **0% expected return** indicates that JNJ's long-term performance is expected to be **similar to the S&P 500**.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

JNJ's recent earnings have shown **mixed results**, with some quarters exceeding expectations while others falling short. The latest earnings report (2024-10-23) reported EPS of 1.12, which was **below analysts' expectations**.  The company's revenue growth has been **consistent**, indicating a healthy overall business performance.

**5. News and Recent Issues:**

**Recent Market Outlook for JNJ:**

* **Positive:** The stock has been resilient in the face of market volatility, driven by its strong brand, consistent dividend, and stable business.
* **Negative:** Concerns remain over the company's potential liability from its talcum powder lawsuits and the impact of competition in the pharmaceutical industry.

**Analyst Opinions:**

Analysts generally have a **mixed view** on JNJ. Some analysts are bullish on the stock due to its dividend, diversified portfolio, and long-term growth potential. However, others are more cautious due to the company's legal challenges and potential for slowing growth in its pharmaceutical division.

**Performance Highlights:**

* **Dividend:** JNJ has a long history of paying dividends, making it an attractive option for income investors.
* **Stability:** The company's diversified portfolio provides a level of stability, making it a potentially safer investment compared to more volatile growth stocks.
* **Growth Potential:** JNJ's ongoing investment in research and development offers potential for future growth in its pharmaceutical and medical device businesses.

**6. Conclusion:**

JNJ's recent performance has been disappointing, with a significant underperformance compared to the S&P 500. The company faces challenges related to legal issues and potential for slowing growth in certain segments. However, its long history of dividend payments, diversified portfolio, and ongoing investment in innovation provide some potential for future growth. Investors should carefully consider these factors and their own risk tolerance before investing in JNJ.

**7. Final Thoughts:**

JNJ is a mature, established company with a diversified portfolio and a strong brand. However, its recent performance and ongoing challenges warrant caution. While its dividend and stability are attractive, investors should carefully weigh the potential risks and rewards before investing in the stock. It is important to monitor future earnings reports, industry trends, and any legal developments that may impact the company's long-term prospects.
